# Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

> **NCT03647163** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vyriad, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumor
- Non Small Cell Lung Cancer
- Neuroendocrine Carcinoma
- Renal Cell Carcinoma (RCC)

## Interventions

- **BIOLOGICAL:** VSV-IFNβ-NIS
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** ipilimumab + nivolumab

## Key facts

- **NCT ID:** NCT03647163
- **Lead sponsor:** Vyriad, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-09
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647163, "Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03647163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*